Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT02487693
PHASE2
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
Sponsor: The First People's Hospital of Changzhou
View on ClinicalTrials.gov
Summary
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
Key Details
Gender
FEMALE
Age Range
30 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2015-07
Completion Date
2040-06
Last Updated
2016-02-23
Healthy Volunteers
No
Conditions
Interventions
PROCEDURE
Radiofrequency ablation
Radiofrequency ablation is performed percutaneously under CT/US guidance
BIOLOGICAL
Cytokine-induced killer cells
The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.